journal
MENU ▼
Read by QxMD icon Read
search

Journal of Oncology Pharmacy Practice

journal
https://www.readbyqxmd.com/read/28077045/association-of-time-to-antibiotics-and-clinical-outcomes-in-adult-hematologic-malignancy-patients-with-febrile-neutropenia
#1
Allison R Butts, Christina Carracedo Bachmeier, Emily V Dressler, Meng Liu, Ann Cowden, Jeff Talbert, Val R Adams
Objective The objective of this study was to determine the clinical impact of time to antibiotic administration in adult inpatients who have hematologic malignancies and develop febrile neutropenia. Methods A retrospective chart review was conducted to screen for all febrile neutropenia events amongst adult hematologic malignancy patients between 1 January 2010 and 1 September 2014. All included patients were admitted to the hospital at the time of fever onset, having been admitted for a diagnosis other than febrile neutropenia...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27799607/adherence-with-capecitabine-a-population-based-analysis-based-on-prescription-refill-data
#2
Laurel Kovacic, Neil de Haan, Mário L de Lemos, Kimberly Schaff, Susan Walisser
Background Patient adherence is important with the increasing use of oral anticancer drugs. Recent studies reported different capecitabine adherence rates based on self-reporting and microelectronic monitoring of the medication bottle. Patient's awareness of being monitored may confound these results. Prescription records provide a larger and more objective dataset for adherence investigation. We report the use of computer algorithm and manual review of prescription and medical documentation to determine the rate of capecitabine adherence...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27000278/breast-cancer-patient-with-everolimus-induced-angioedema-a-rare-occurrence-with-potential-for-serious-consequences
#3
Neil Roe, Jennifer D Twilla, Benjamin Duhart, Brian Wheeler
Background The development of angioedema is a rare yet serious clinical event that may develop due to an adverse drug reaction. Rapid recognition and treatment of this adverse reaction is critical for optimal patient outcomes; however, prevention of this occurrence is preferred. Case report A 59-year-old woman presented to the emergency department with lingual angioedema caused by the addition of everolimus to her medication regimen. The patient improved after withdrawal of the offending agent and standard treatment...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26988246/improving-adherence-to-the-epic-beacon-ambulatory-workflow
#4
Ellen Chackunkal, Vishnuprabha Dhanapal Vogel, Meredith Grycki, Diana Kostoff
Computerized physician order entry has been shown to significantly improve chemotherapy safety by reducing the number of prescribing errors. Epic's Beacon Oncology Information System of computerized physician order entry and electronic medication administration was implemented in Henry Ford Health System's ambulatory oncology infusion centers on 9 November 2013. Since that time, compliance to the infusion workflow had not been assessed. The objective of this study was to optimize the current workflow and improve the compliance to this workflow in the ambulatory oncology setting...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26988245/acute-encephalopathy-with-combination-dabrafenib-trametinib-therapy
#5
Jalyn Cooper, Dheeraj Kodali, Gerald M Higa
Biomarkers have improved the clinical application of numerous targeted agents used to treat solid tumors. In melanoma, the finding that approximately 60% of tumor cells harbor specific Val600 mutations of BRAF has increased the likelihood of response to certain agents aimed at inhibiting the mutant kinase. While dabrafenib is an effective anti-tumor agent with acceptable tolerability in patients with BRAF-mutated melanoma, we report the development (and outcome) of a previously unpublished acute toxic reaction observed in a patient receiving the drug...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26983449/observational-study-of-trastuzumab-related-cardiotoxicity-in-early-and-metastatic-breast-cancer
#6
L R Grazziotin, P D Picon
Introduction Trastuzumab-related cardiotoxicity has been a major concern in clinical practice, since observational studies have shown higher incidences than that reported in clinical trials. We aim to measure the incidence of trastuzumab-related cardiotoxicity in patients with early and metastatic breast cancer in the south of Brazil. Methods Multicenter prospective observational study, which included 109 patients with early or metastatic HER-2+ breast cancer undergoing any trastuzumab-based regimen. Cardiac events were measured by transthoracic echocardiography assessments and by signs and symptoms of heart failure...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26970572/risk-of-graft-versus-host-disease-with-rituximab-containing-conditioning-regimens-in-allogeneic-hematopoietic-stem-cell-transplant
#7
Bernard L Marini, Denise Markstrom, David Frame
Graft-versus-host disease represents a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant patients. There is growing evidence that B lymphocytes may play a role in the pathogenesis of acute graft-versus-host disease. The purpose of this retrospective cohort study was to evaluate the efficacy of rituximab-containing conditioning regimens in decreasing graft-versus-host disease in allogeneic hematopoietic stem cell transplant patients who received standardized tacrolimus-based graft-versus-host disease prophylaxis regimens...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26946529/late-onset-robust-curly-hair-growth-in-a-patient-with-braf-mutated-metastatic-melanoma-responding-to-dabrafenib
#8
Matthew Keating, Constantin A Dasanu
Development of curly hair has been infrequently described in association with BRAF inhibitors in clinical trials, and usually affects patients between 6 and 24 weeks of therapy. The curly hair is typically preceded by initial hair thinning or even diffuse alopecia. We report herein an occurrence of late-onset robust curly head hair growth in a patient with metastatic melanoma responding well to dabrafenib, without being preceded by hair thinning. The curly hair in our patient developed at 11 months of therapy with dabrafenib...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26921085/drug-interactions-with-aprepitant-or-fosaprepitant-review-of-literature-and-implications-for-clinical-practice
#9
Anna Dushenkov, Julie Kalabalik, Antonia Carbone, Paiboon Jungsuwadee
Purpose Aprepitant and its parenteral formulation fosaprepitant are widely used for the prevention of chemotherapy-induced nausea and vomiting. Aprepitant exerts modest inhibitory effect on CYP3A4 and modest inductive effect on CYP2C9 substrates such as some antineoplastics and multiple other medications. This article is aimed to provide pharmacists and other healthcare professionals with an updated summary of drug-drug interactions of aprepitant/fosaprepitant and implications for clinical practice. Method We reviewed publications reporting drug-drug interactions between aprepitant/fosaprepitant and other medications...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26911480/evaluation-of-a-rapid-hydration-protocol-safety-and-effectiveness
#10
Sean Meredith, Jane Hilliard, Regis Vaillancourt
Background The Children's Hospital of Eastern Ontario (CHEO) has implemented a rapid hydration protocol that may reduce the time required to achieve urine specific gravity and pH targets prior to chemotherapy. Objective The aim of this study was to determine if a rapid hydration protocol resulted in a shorter time to chemotherapy administration and during peak staffing levels without increasing adverse effects. Methods A retrospective chart review was conducted using data from electronic and paper medical charts, the hematology/oncology whiteboard, and video recordings...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26911478/evaluating-the-patient-perceived-impact-of-clinical-pharmacy-services-and-proactive-follow-up-care-in-an-ambulatory-chemotherapy-unit
#11
Andrea Crespo, Malgorzata Tyszka
Purpose To evaluate the patient-perceived impact of delivery of clinical pharmacy services, including a proactive follow-up program, on patient understanding, satisfaction, and toxicity management. Methods Patients who had received clinical pharmacy services at their initial chemotherapy treatment were identified and asked to complete a 20-point survey at the second or subsequent treatment. The services that the survey evaluated consist of face-to-face education during the first treatment and proactive telephone follow-up 3 to 7 days later...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26908232/adverse-reactions-in-mrcc-patients-documented-in-routine-practice-by-german-office-based-oncologists-and-uro-oncologists
#12
Norbert Marschner, Lothar Müller, Axel Münch, Klaus Blumenstengel, Ulrich Hutzschenreuter, Sabine Busies
Background Signal transduction inhibitors (STIs) have considerably improved treatment of advanced/metastasized renal cell carcinoma (mRCC). Most safety data for these drugs are derived from clinical trials. The purpose of this study was to evaluate which adverse drug reactions are documented during first-line treatments in routine clinical practice. Patients and methods The ongoing prospective German mRCC clinical registry is recruiting patients in 110 oncology and urology outpatient centers. Data from the first 250 patients who had completed first-line treatment were analyzed regarding adverse drug reactions (ADRs) documented in patients' medical records...
June 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26970573/ibrutinib-associated-tumor-lysis-syndrome-in-a-patient-with-mantle-cell-lymphoma-a-case-report
#13
Varinder Kaur, Arjun Swami
Mantle cell lymphoma accounts for 5-7% of all non-Hodgkin's lymphomas. Under the current WHO classification, it is categorized as an indolent B cell lymphoma, but has an aggressive clinical course. New insights into leukemogenic molecular pathways of mantle cell lymphoma have uncovered unique therapeutic targets. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is the newest drug in the arsenal that has shown promising efficacy in relapsed mantle cell lymphoma. Long-term studies have shown that grade 3 or 4 adverse events are infrequent...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26946531/late-onset-pericardial-tamponade-bilateral-pleural-effusions-and-recurrent-immune-monoarthritis-induced-by-ipilimumab-use-for-metastatic-melanoma
#14
Constantin A Dasanu, Tiffany Jen, Ryszard Skulski
While an important agent in the contemporary anti-melanoma armamentarium, ipilimumab is associated with serious immune reactions including late immune-mediated side effects. Recently, a case of late-onset acute pericarditis with tamponade was reported at 12 weeks after the last dose of ipilimumab. While polyarthralgia rheumatica has been previously documented with ipilimumab, we were not able to find any reports of recurrent monoarthritis with the use of this agent. Therefore, we present herein a unique case featuring a patient with late-onset autoimmune pleuropericarditis leading to cardiac tamponade at 24 weeks post-ipilimumab and recurrent late immune knee arthritis at 8 and 32 weeks, respectively...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26911479/irinotecan-induced-dysarthria-a-case-report-and-review-of-the-literature
#15
Krista G Ramirez, Marla D Koch, William J Edenfield
Irinotecan-induced dysarthria has been reported in the literature, but the underlying mechanism of this neurotoxicity remains unclear. Here, we present a 35-year-old female with metastatic colon cancer who experienced dysarthria during irinotecan infusion. Her symptoms were decreased and eventually eliminated with subsequent increases in infusion time. When the patient returned to original 90 min infusion time, symptoms were significantly reduced in both severity and duration as compared to the first infusion...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26911477/flipped-script-for-gefitinib-a-reapproved-tyrosine-kinase-inhibitor-for-first-line-treatment-of-epidermal-growth-factor-receptor-mutation-positive-metastatic-nonsmall-cell-lung-cancer
#16
Brian S Bogdanowicz, Matthew A Hoch, Megan E Hartranft
Purpose The approval history, pharmacology, pharmacokinetics, clinical trials, efficacy, dosing recommendations, drug interactions, safety, place in therapy, and economic considerations of gefitinib are reviewed. Summary Lung cancer is one of the most commonly diagnosed cancers and is the leading cause of cancer death. Platinum-based chemotherapy and tyrosine kinase inhibitors, such as erlotinib and afatinib, are recommended therapies for nonsmall cell lung cancer. The European Medicines Association based their approval of gefitinib on the randomized, multicenter Iressa Pan-Asia Study (IPASS, NCT00322452) and a single-arm study showing effectiveness in Caucasians (IFUM, NCT01203917)...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26864940/healthcare-resource-use-and-costs-associated-with-renal-impairment-in-us-patients-with-bone-metastases-from-solid-tumors
#17
Yi Qian, Jorge Arellano, Debajyoti Bhowmik, Erin Thomson, David M Smith, Guy Hechmati, Xue Song
Introduction During cancer progression, more than half of patients develop renal insufficiency, including chronic kidney disease. The primary and secondary objectives of this study were to estimate healthcare resource use and costs, respectively, associated with renal impairment in patients with bone metastases from solid tumors in the United States. Methods and materials This was a retrospective, observational cohort study conducted using administrative claims data for individuals with solid tumors and bone metastases...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26854267/pharmacists-roles-in-oncology-pharmacy-services-results-of-a-global-survey
#18
Lisa M Holle, Christy S Harris, Alexandre Chan, Rebecca J Fahrenbruch, Bonnie A Labdi, Jocelyn E Mohs, Leann B Norris, Janelle Perkins, Cory M Vela
Background Oncology pharmacists are capable of providing medication therapy management (MTM) because of their level of training, practice experiences, and responsibilities. Very little data exist about their current practice, including changing roles in the multidisciplinary team, overall impact, and effects in the education of patients and healthcare professionals. Methods A 70-item survey about oncology pharmacists' activities in oral chemotherapy programs, MTM, and collaborative practice agreements (CPAs) was deployed using a web survey tool (Qualtrics, Provo, UT, USA), targeting pharmacist members of American College of Clinical Pharmacy (ACCP) Hematology/Oncology Practice and Research Network (PRN)...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26854266/safety-of-anticoagulation-in-thrombocytopenic-patients-with-hematologic-malignancies-a-case-series
#19
Peter M Campbell, Cindy Ippoliti, Sapna Parmar
The incidence of venous thromboembolism is greater among cancer patients than the general patient population, with recurrence rates also much higher in patients with cancer diagnoses. Patients with hematologic malignancies often experience prolonged periods of thrombocytopenia throughout their disease course, making therapeutic anticoagulation a challenge. We describe 13 cases of patients with hematologic malignancies that were therapeutically anticoagulated with either low-molecular-weight heparin or unfractionated heparin during periods of severe thrombocytopenia (platelet counts < 50 × 10(9)/µL)...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26830549/incidence-of-hypocalcemia-in-patients-receiving-denosumab-for-prevention-of-skeletal-related-events-in-bone-metastasis
#20
Prakirthi Yerram, Shraddha Kansagra, Osama Abdelghany
Background Denosumab therapy is commonly used for the prevention of skeletal-related events in patients with bone metastasis. However, a common side effect of denosumab is hypocalcemia. Objective The aim of the study is to determine the incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis and evaluate risk factors for developing hypocalcemia. Methods This was a retrospective medication use evaluation reviewing the incidence of hypocalcemia in patients receiving outpatient denosumab for prevention of skeletal-related events at Yale-New Haven Hospital...
April 2017: Journal of Oncology Pharmacy Practice
journal
journal
32324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"